Post by IXICO

Today IXICO announced its 2025 financial results demonstrating how the disciplined execution of its “Innovate Lead Scale" strategy has delivered 13% revenue growth with commercial traction further accelerating into FY26, resulting in a 27% increase to the order book since the FY25 year-end. Bram Goorden, CEO of IXICO, said: “2025 has been a pivotal year for IXICO witnessing a strong return to growth, an extension of our leadership in neuroimaging and promising early progress from the Innovate Lead Scale strategy. The continued development of scientific capabilities through our next-generation IXI™ platform uniquely places IXICO to deliver impact to biopharma and diagnostics partners, helping accelerate the development of much-needed treatments for neurodegenerative disease. The commercial momentum experienced in FY25 has continued into the new financial year, and together with our incredible group of people and a clear strategy to advance precision medicine, we enter 2026 with confidence and excitement.” Read more: https://lnkd.in/eVCWGXUK